series-c-plus
Stage
About
Gain Therapeutics develops allosteric small-molecule therapeutics using AI-supported 3D structural biology and physics-based models. Its lead candidate, GT-02287, is being developed for GBA-linked Parkinson's disease and is in clinical trials.
Explore Gain Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.